Cargando…

Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment

OBJECTIVE/PURPOSE: Previously patient reported quality of life (QOL) was reported in men with prostate cancer a mean 2 and 6 years post treatment with open radical prostatectomy (RP), 3D conformal radiation therapy (3D CRT), or (125)I low dose rate (LDR) brachytherapy (BT). Herein we update the resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Seymour, Zachary A., Daignault-Newton, Stephanie, McLaughlin, P.W., Sandler, Howard, Jackson, William, Johnson, Skyler B., Miller, David, Wei, John, Sanda, Martin, Hamstra, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256969/
https://www.ncbi.nlm.nih.gov/pubmed/35813938
http://dx.doi.org/10.1016/j.ctro.2022.05.007
_version_ 1784741231548432384
author Seymour, Zachary A.
Daignault-Newton, Stephanie
McLaughlin, P.W.
Sandler, Howard
Jackson, William
Johnson, Skyler B.
Miller, David
Wei, John
Sanda, Martin
Hamstra, Daniel A.
author_facet Seymour, Zachary A.
Daignault-Newton, Stephanie
McLaughlin, P.W.
Sandler, Howard
Jackson, William
Johnson, Skyler B.
Miller, David
Wei, John
Sanda, Martin
Hamstra, Daniel A.
author_sort Seymour, Zachary A.
collection PubMed
description OBJECTIVE/PURPOSE: Previously patient reported quality of life (QOL) was reported in men with prostate cancer a mean 2 and 6 years post treatment with open radical prostatectomy (RP), 3D conformal radiation therapy (3D CRT), or (125)I low dose rate (LDR) brachytherapy (BT). Herein we update the results 15 years post-treatment QOL. MATERIALS/METHODS: The Expanded Prostate Cancer Index (EPIC) domains were scored with differences evaluated at a median 15.8 years follow up based upon mean EPIC summary domains by ANOVA with pairwise post-hoc comparisons adjusted for age. Patient differences of current survey from first cross-section are reported as median change in summary score for each treatment group at median of 2.2 and 6.0, and 15.8 years. RESULTS: Among men still alive response rate was 52% in BT, 60% in 3D CRT, and 62% in RP resulting in 30, 41, and 330 QOL questionnaires to evaluate for each corresponding modality at median follow up of 15.8 years. Men were a mean 75.3, 83.6, and 79.3 years of age after RP, 3DCRT, and BT, respectively. At a median of 15.8 years, there were largely persistent differences in EPIC domains without substantial evolution in QoL from middle time points. Persistent worsening in urinary irritative and bowel domain with 3DRT or BT compared to RP. Trend towards worse urinary incontinence with RP were noted without statistical differences within radiotherapy options. CONCLUSION: As the EPIC patient reported outcomes with the longest follow-up, these data uniquely reveal temporal trends from 2 to 15 years post treatment. However, the treatment modalities of open RP, 3D CRT without image guidance or intensity modulation, and BT without peripheral loading or MRI guidance may not reflect modern techniques.
format Online
Article
Text
id pubmed-9256969
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92569692022-07-07 Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment Seymour, Zachary A. Daignault-Newton, Stephanie McLaughlin, P.W. Sandler, Howard Jackson, William Johnson, Skyler B. Miller, David Wei, John Sanda, Martin Hamstra, Daniel A. Clin Transl Radiat Oncol Article OBJECTIVE/PURPOSE: Previously patient reported quality of life (QOL) was reported in men with prostate cancer a mean 2 and 6 years post treatment with open radical prostatectomy (RP), 3D conformal radiation therapy (3D CRT), or (125)I low dose rate (LDR) brachytherapy (BT). Herein we update the results 15 years post-treatment QOL. MATERIALS/METHODS: The Expanded Prostate Cancer Index (EPIC) domains were scored with differences evaluated at a median 15.8 years follow up based upon mean EPIC summary domains by ANOVA with pairwise post-hoc comparisons adjusted for age. Patient differences of current survey from first cross-section are reported as median change in summary score for each treatment group at median of 2.2 and 6.0, and 15.8 years. RESULTS: Among men still alive response rate was 52% in BT, 60% in 3D CRT, and 62% in RP resulting in 30, 41, and 330 QOL questionnaires to evaluate for each corresponding modality at median follow up of 15.8 years. Men were a mean 75.3, 83.6, and 79.3 years of age after RP, 3DCRT, and BT, respectively. At a median of 15.8 years, there were largely persistent differences in EPIC domains without substantial evolution in QoL from middle time points. Persistent worsening in urinary irritative and bowel domain with 3DRT or BT compared to RP. Trend towards worse urinary incontinence with RP were noted without statistical differences within radiotherapy options. CONCLUSION: As the EPIC patient reported outcomes with the longest follow-up, these data uniquely reveal temporal trends from 2 to 15 years post treatment. However, the treatment modalities of open RP, 3D CRT without image guidance or intensity modulation, and BT without peripheral loading or MRI guidance may not reflect modern techniques. Elsevier 2022-06-01 /pmc/articles/PMC9256969/ /pubmed/35813938 http://dx.doi.org/10.1016/j.ctro.2022.05.007 Text en © 2022 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Seymour, Zachary A.
Daignault-Newton, Stephanie
McLaughlin, P.W.
Sandler, Howard
Jackson, William
Johnson, Skyler B.
Miller, David
Wei, John
Sanda, Martin
Hamstra, Daniel A.
Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment
title Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment
title_full Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment
title_fullStr Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment
title_full_unstemmed Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment
title_short Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment
title_sort patient reported outcomes for quality of life (qol) by expanded prostate cancer index (epic) on average 15 years post treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256969/
https://www.ncbi.nlm.nih.gov/pubmed/35813938
http://dx.doi.org/10.1016/j.ctro.2022.05.007
work_keys_str_mv AT seymourzacharya patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT daignaultnewtonstephanie patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT mclaughlinpw patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT sandlerhoward patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT jacksonwilliam patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT johnsonskylerb patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT millerdavid patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT weijohn patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT sandamartin patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment
AT hamstradaniela patientreportedoutcomesforqualityoflifeqolbyexpandedprostatecancerindexepiconaverage15yearsposttreatment